The FDA regulations for RPM (Remote Patient Monitoring) in 2023 require that all RPM devices and software meet strict quality and safety standards.
These standards include:
- ensuring data privacy and security;
- accuracy of measurements;
- reliability of communication between the device and healthcare providers.
The regulations also require clear instructions for use, proper labeling, and proper training for healthcare providers and patients. Additionally, the FDA requires manufacturers to conduct rigorous testing and assessments before their RPM devices and software can be approved.
On the 14th of September 2023, the FDA’s Center for Devices and Radiological Health (CDRH) issued updated final guidance on the Breakthrough Devices Program aimed at advancing health equity, supporting innovation, and ensuring patient access to life-saving medical devices.
In this article, we delve into the definition of RPM and outline key takeaways from the FDA’s latest announcements.
What is Remote Patient Monitoring (RPM)?
Remote Patient Monitoring (RPM) is a healthcare approach that uses technology to keep track of a patient’s health data from a distance. Instead of patients needing to visit a hospital or clinic, RPM allows healthcare providers to monitor their health conditions remotely. This is done through special devices that collect and send data about the patient’s vital signs, symptoms, and other health information to the healthcare team. RPM helps doctors closely monitor patients’ health and provide timely care, even when they are not physically present at the medical facility.
Breakthrough Devices Program Overview
The Breakthrough Devices Program, launched in 2015, is a vital conduit for bringing innovative medical technologies to market. This voluntary program is designed specifically for certain medical devices and device-led combination products capable of delivering more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Its primary goal is expediting the development, assessment, and review processes for premarket approval, 510(k) clearance, and De Novo marketing authorization, ensuring timely access for patients and healthcare providers.
NOTE: As of the latest data available, the FDA’s Center for Devices and Radiological Health (CDRH) has granted Breakthrough Device designation to 831 devices and authorized marketing for 77 devices with this designation. These devices span a wide range of intended uses and regulatory pathways, showcasing the program’s influence within the industry.
The Breakthrough Devices Program seeks to provide patients and healthcare providers quicker access to these innovations by expediting the development, assessment, and review processes.
Is your device eligible for Breakthrough Device designation?
Devices that are required to submit applications for premarket approval, premarket notification, or requests for reclassification can be considered for a Breakthrough Device designation if they meet the following conditions:
What it means for the Software Development Industry
The recent update to final guidance for the Breakthrough Devices Program, dated June 30, 2023, is poised to impact not just the medical device sector but also hold potential relevance for the software development industry.
The key objective
The updated guidance aims to leverage the interactive nature of the Breakthrough Devices Program to promote health equity. This aligns with CDRH’s strategic priority to advance health equity and the agency’s obligations under the SUPPORT Act. Notably, the guidance clarifies that the Breakthrough Devices Program may be available for certain non-addictive medical products aimed at treating pain or addiction.
New opportunities
This guidance opens up opportunities for innovation and collaboration. Medical devices are increasingly reliant on software and digital components, making software development a critical aspect of their design and functionality.
The guidance also outlines how CDRH will consider technologies and device features that address health disparities and promote health equity, especially in populations that experience disparities in healthcare access. This emphasis on addressing disparities presents an avenue for software developers to create solutions that bridge gaps in healthcare delivery.
The software development industry’s involvement in the development of medical devices is further underscored by the CDRH Regulatory Science Tools (RSTs), which are used extensively across different devices. These tools have played a crucial role in many Breakthrough Devices that have received marketing authorization. For instance, additive manufacturing guidance has facilitated innovation in 3D printing, a technology widely used in medical device production.
The “more effective” criterion
The updated guidance clarifies the FDA’s interpretation of the “more effective” criterion, emphasizing the need for a device to make a clinically meaningful impact while considering risks and benefits compared to standard care. This clarification provides software developers with clear criteria for demonstrating the effectiveness of their solutions within the medical device context.
In addition to the Breakthrough Devices Program, CDRH has launched the Total Product Life Cycle (TPLC) Advisory Program (TAP) Pilot in 2023. This initiative aims to streamline medical device development, reduce time-to-market, and foster collaboration between the FDA, industry stakeholders, and healthcare providers.
TAP Pilot
TAP’s focus is on early engagement, and strategic input allows software developers to participate in shaping the future of medical device technology.
The program will gather input from patients, healthcare providers, and payers throughout the development process, aligning with the industry’s user-centered design and agile development principles.
By involving stakeholders early and often, developers can better align their solutions with patient needs and navigate the complex coding, coverage, reimbursement, and market adoption landscape.
Summary
The software used in healthcare must meet the highest standards of reliability, security, and compliance with regulatory guidelines.
The FDA’s updated guidance for the Breakthrough Devices Program and the introduction of the TAP Pilot provide the software development industry with unique opportunities to contribute to the advancement of medical technology. By aligning with the program’s goals of promoting health equity and streamlining the device development process, software developers can play a pivotal role in shaping the future of healthcare innovation.
If you need help developing secure and reliable RPM solutions – get in touch with us.
Gera-IT – secret software development partner for many Healthcare startups and businesses
Tags: FDA regulations, healthcare, Remote Patient Monitoring